State Street SPDR S&P Biotech ETF (XBI) Stock Overview
Explore State Street SPDR S&P Biotech ETF’s financial performance, market position, analyst ratings, and future outlook.
State Street SPDR S&P Biotech ETF (XBI)
Key Financials
Key Financials
Market Cap
8.2B
P/E Ratio
N/A
EPS (TTM)
$8.18
ROE
0.00%
XBI Stock Analysis & Investment Overview (AMEX)
Our AI-powered analysis of State Street SPDR S&P Biotech ETF (AMEX: XBI) gives investors deep insight into how the stock performs on the AMEX exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, State Street SPDR S&P Biotech ETF's AMEX-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of XBI on the AMEX shows an RSI of 45.36, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $156.11 for the AMEX listing.
Key metrics behind State Street SPDR S&P Biotech ETF's AMEX-traded stock include a P/E ratio of N/A and a market capitalization of 8.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of XBI on the AMEX.